

Hospital Infection Therapeutics Market Report 2021-26: Outlook, Demand, Key player Analysis

Looking forward, IMARC Group expects the global hospital infection therapeutics market to grow at a CAGR of 2.4% during 2021-2026.

SHERIDAN, WYOMING, UNITED STATES, October 20, 2021 /EINPresswire.com/ -- According to IMARC Group's latest report, titled "[Hospital Infection Therapeutics Market](#): Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026", The global hospital infection therapeutics market reached a value of around US\$ 11 Billion in 2020. Hospital

infection therapeutics refers to drugs or medications used to treat diseases or infections. They can be acquired from viral, bacterial and fungal pathogens present in hospitals, nursing homes, rehabilitation centers, outpatient clinics, and other treatment centers. Therapeutics, such as antibacterial, antiviral, antifungal, and infection-based drugs, are used to prevent hospital-acquired infections (HAIs) like urinary tract infections (UTI), pneumonia, surgical site infection, and bloodstream infections (BSI).

Request for a PDF sample of this report: <https://www.imarcgroup.com/hospital-infection-therapeutics-market/requestsample>

The global hospital infection therapeutics market is primarily driven by the rising prevalence of chronic diseases that have increased hospital admissions and cases of HAIs. The growing geriatric population and rising healthcare expenditure are also escalating the demand for these therapeutics. Furthermore, there has been a development of advanced therapies, drugs, vaccines and coverings can be used for the treatment of infections with specific symptoms. Moreover, extensive investment in research and development (R&D) activities to develop new HAI drugs, such as Zerbaxa by Merck & Co., for the treatment of ventilator-associated bacterial pneumonia (VABP), are expected to influence the market growth in the near future. Looking



Hospital Infection Therapeutics Market

forward, IMARC Group expects the global hospital infection therapeutics market to grow at a CAGR of 2.4% during 2021-2026.

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Competitive Landscape with Key Players:

Allergan Plc (AbbVie Inc.)
AstraZeneca Plc
Bayer Aktiengesellschaft
Bristol-Myers Squibb Company
Hoffmann-La Roche AG (Roche Holding AG)
Gilead Sciences Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc
Pfizer Inc.
Sanofi S.A.

Market Segmentation:

Breakup by Drug Type:

Anti-bacterial Drugs
Anti-fungal Drugs
Anti-viral Drugs
Others

Breakup by Indication:

Blood Stream Infections
Urinary Tract Infections
Surgical Site Infections
Pneumonia
Others

Breakup by Region:

North America (United States, Canada)
Europe (Germany, France, United Kingdom, Italy, Spain, Others)
Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
Latin America (Brazil, Mexico, Others)

Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)

Ask Analyst for Customization and Explore full report with TOC & List of Figures:

<https://www.imarcgroup.com/hospital-infection-therapeutics-market>

We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

Key highlights of the report:

Market Performance (2015-2020)

Market Outlook (2021-2026)

Market Trends

Market Drivers and Success Factors

The Impact of COVID-19 on the Global Market

Value Chain Analysis

Structure of the Global Market

Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Related Reports by IMARC Group:

Apheresis Equipment Market: <https://www.imarcgroup.com/apheresis-equipment-market>

RNA Interference Drug Delivery Market: <https://www.imarcgroup.com/rna-interference-drug-delivery-market>

Multiple Sclerosis Therapies Market: <https://www.imarcgroup.com/multiple-sclerosis-therapies-market>

Portable Medical Ventilators Market: <https://www.imarcgroup.com/portable-medical-ventilators-market>

Nucleic Acid Labelling Market: <https://www.imarcgroup.com/nucleic-acid-labelling-market>

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Elena Anderson

IMARC Services Private Limited

+1 6317911145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/554289989>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.